Is Tukysa a subsidiary of Pfizer?

Tukysa is a product brand of Pfizer, obtained through the December 2023 Seagen acquisition for approximately $43 billion. It is not a separate company.

Is Tukysa publicly traded?

No. It is a drug brand. Its owner Pfizer trades on the NYSE under ticker PFE.

When was Tukysa approved?

The FDA approved Tukysa in April 2020 for HER2-positive metastatic breast cancer and added a HER2-positive colorectal cancer indication in January 2023.

Who developed Tukysa?

Tukysa was developed by Seagen, the Bothell, Washington oncology company formerly called Seattle Genetics. Pfizer acquired Seagen in 2023.

What is Tukysa's market position?

Tukysa holds a niche in later-line HER2-positive metastatic breast cancer, distinguished by its ability to cross the blood-brain barrier and treat brain metastases. It also treats HER2-positive colorectal cancer after its 2023 label expansion.

Healthcare & Pharmaceuticals

Who Owns Tukysa?

Tukysa is owned by Pfizer Inc. (NYSE: PFE), which acquired the drug through its December 2023 purchase of Seagen for approximately $43 billion. Tukysa (tucatinib) is an oral HER2 tyrosine kinase inhibitor first FDA approved in April 2020 for HER2-positive metastatic breast cancer, notable for its activity against brain metastases.

Parent Company

Pfizer Inc.

Acquired

2023

Status

Publicly Traded

Headquarters

Bothell, Washington, USA

Tukysa Timeline

1849

Pfizer Inc.

Parent company established in New York, New York, USA

Company Founded

2020

Tukysa

Founded by Seagen Inc. (original development)

Founded

2023

Acquired by Pfizer Inc.

Pfizer Inc. acquired Tukysa

Acquired

GlobalOfficial Website

Who Owns Tukysa?

Parent Company: Pfizer Inc.
Ownership Type: Subsidiary
Acquisition Year: 2023
Company Type: Publicly Traded
Stock Ticker: NYSE: PFE

Brand	Parent Company	Ownership Type
Tukysa	Pfizer Inc.	Subsidiary

Where to Buy

Disclosure: We may earn commission from purchases

Tukysa on Amazon

History of Tukysa

Founded: 2020
Founders: Seagen Inc. (original development)
Acquired by Pfizer Inc.: 2023

Tucatinib was developed at Seattle Genetics as a selective HER2 tyrosine kinase inhibitor. HER2-positive breast cancer, an aggressive subtype driven by HER2 protein overexpression, had been transformed by antibody therapies like Herceptin, but brain metastases remained poorly controlled because large antibody molecules do not cross the blood-brain barrier effectively.

Tukysa's distinction is that it is a small molecule that penetrates the central nervous system. The HER2CLIMB trial demonstrated that adding tucatinib to trastuzumab and capecitabine improved overall survival and progression-free survival in patients who had received prior HER2 therapies, including a meaningful benefit in the brain metastasis population where previous options were limited.

The FDA approved Tukysa in April 2020 for HER2-positive metastatic breast cancer after prior treatment, in combination with trastuzumab and capecitabine. The approval launched the drug into the later-line setting where its brain penetration made it the preferred option for patients with or at risk of CNS disease.

In January 2023, the FDA expanded the label to HER2-positive colorectal cancer, an accelerated approval for RAS wild-type disease after prior treatment, extending Tukysa into a second tumor type. Pfizer completed its Seagen acquisition in December 2023, bringing Tukysa into the Pfizer portfolio as one of three commercial Seagen oncology products.

Under Pfizer, Tukysa continues to generate revenue as a niche but meaningful oncology product within the company's $62.6 billion FY2025 total, with ongoing trials exploring earlier-line breast cancer use.

About Pfizer Inc.

What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.

Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.

Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.

Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.

How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.

Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.

What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.

Founded: 1849
Headquarters: New York, New York, USA
Company Type: Publicly Traded
Stock: NYSE: PFE
Revenue: $62.6 billion (FY2025)
Employees: approximately 88,000

Visit Pfizer Inc. website

View full company profile for Pfizer Inc.

Where Is Tukysa Made / Based?

Headquarters: Bothell, Washington, USA
Manufacturing / Operations: United States

Tukysa Categories & Tags

Oncology Breast Cancer Her2 Prescription Drug Cancer Treatment

Tukysa Recalls & Controversies

Tukysa's labeled safety profile includes diarrhea and hepatotoxicity as the principal toxicities, managed through monitoring and dose adjustment in the combination regimen. Post-marketing surveillance has not produced safety actions or recalls.

The drug's niche positioning limits the commercial controversy it attracts, though pricing in line with specialty oncology products draws the standard criticism applied to the category. Its clinical value in the brain metastasis population is well documented, mitigating the competitive pressure from larger HER2 agents.

Tukysa Ownership: Pros & Cons

Advantages

+Unique CNS penetration gives it a defensible niche in HER2 brain metastasis treatment
+Pfizer's global commercial infrastructure supports broader international penetration
+Colorectal indication expands addressable use beyond breast cancer
+Part of a diversified ADC and targeted-therapy oncology platform from Seagen

Considerations

-Enhertu's dominance in earlier-line HER2 disease compresses Tukysa into later lines
-Small revenue contribution relative to the $43 billion Seagen acquisition price
-Diarrhea and hepatotoxicity require active management in combination regimens
-Niche population limits long-term growth potential without new indication wins

Frequently Asked Questions About Tukysa

Sources & Further Reading

Competitors to Tukysa

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
IbranceSister Brand	Pfizer	USA	2015	Mass market	Global	All Genders
Herceptin	Roche	USA (Genentech)	1998	Premium	Global	All-ages
Kadcyla	Roche	Switzerland	2013	Mass market	Global	All Genders
Opdivo	Bristol Myers Squibb	USA	2014	Mass market	Global	All Genders
Perjeta	Roche	USA (Genentech)	2012	Premium	Global	Womens
Taxotere	Sanofi	France	1996	Established	Global	Unisex